

- 34 -

### Claims

1. A method of treating lymphedema comprising administering an effective amount of a composition to a patient in need thereof, the composition  
5 comprising cyclodextrin or a pharmaceutically acceptable salt, solvate or prodrug thereof;  
wherein an interior cavity of the cyclodextrin is unoccupied.
2. A composition for treating lymphedema in a patient in need thereof, the  
10 composition comprising cyclodextrin or a pharmaceutically acceptable salt, solvate or prodrug thereof;  
wherein an interior cavity of the cyclodextrin is unoccupied.
3. Use of a composition in the manufacture of a medicament for treating  
15 lymphedema, the composition comprising cyclodextrin or a pharmaceutically acceptable salt, solvate or prodrug thereof;  
wherein an interior cavity of the cyclodextrin is unoccupied.
4. The method, composition or use according to any one of claims 1 to 3,  
20 wherein the composition to be administered ameliorates or reduces tissue edema, lymphatic function, lipid accumulation, tissue cholesterol, fibrosis, inflammation, or a combination thereof.
5. The method, composition or use according to any one of claims 1 to 4,  
25 wherein the composition is to be administered on alternate days.
6. The method, composition or use according to any one of claims 1 to 5,  
wherein the composition is to be administered in at least 2 doses over at least  
4 days.  
30
7. The method, composition or use according to any one of claims 1 to 6,  
wherein the composition is to be administered at a dose of about 0.5 g/kg to

- 35 -

about 10 g/kg.

8. The method, composition or use according to any one of claims 1 to 7,  
wherein the composition is to be administered to a patient in need thereof who  
5 has lymphedema with a severity of stage 2 or less.

9. A composition comprising cyclodextrin;  
wherein an interior cavity of the cyclodextrin is unoccupied.

10 10. The composition according to claim 9, wherein a weight ratio of  
cyclodextrin to composition is about 0.1 %w/w to about 50 %w/w.

11. The composition according to claim 9 or 10, wherein the cyclodextrin is  
derivatised with alkyl, alkenyl, alkynyl, alkoxy, hydroalkyl, halo, haloalkyl,  
15 haloalkenyl, haloalkynyl, alkylacyl, alkenylacyl, alkynylacyl, aryl, or alkylaryl.

12. The composition according to any one of claim 9 to 11, wherein the  
cyclodextrin is derivatised with methyl, ethyl, propyl, hydromethyl, hydroethyl,  
hydropropyl, fluoro, chloro, bromo, benzyl, or phenyl.

20 13. The composition according to any one of claim 9 to 12, wherein the  
cyclodextrin is derivatised 1 to 24 times.

14. The composition according to any one of claim 9 to 13, wherein the  
25 cyclodextrin is a  $\beta$ -cyclodextrin selected from methyl- $\beta$ -cyclodextrin, 2-  
hydroxylpropyl- $\beta$ -cyclodextrin, or a combination thereof.

15. The composition according to any one of claim 9 to 14, wherein the  
interior cavity of the cyclodextrin has a diameter of about 5.5 Å to about 9.7 Å.

30 16. The composition according to any one of claim 9 to 15, wherein the  
interior cavity of the cyclodextrin is unoccupied or occupied with an inert  
molecule.

- 36 -

17. The composition according to any one of claims 9 to 16, further comprising an excipient selected from stabilisers, solubilisers, emulsifiers, surfactants, water-soluble polymers, pH modifiers, fillers, binders, pigments,  
5 disintegrants, antioxidants, preservatives, emollients, silicones, penetration enhancers, lubricants and perfume.

18. The composition according to claim 17, wherein the excipient is selected from microcrystalline cellulose; metallic salts of acids such as aluminium  
10 stearate, calcium stearate, magnesium stearate, sodium stearate, and zinc stearate; fatty acids, hydrocarbons and fatty alcohols such as stearic acid, palmitic acid, liquid paraffin, stearyl alcohol, and palmitol; fatty acid esters such as glyceryl (mono- and di-) stearates, triglycerides, glyceryl (palmitic stearic) ester, sorbitan monostearate, saccharose monostearate, saccharose  
15 monopalmitate, and sodium stearyl fumarate, alkyl sulfates such as sodium lauryl sulfate and magnesium lauryl sulfate; polymers such as polyethylene glycols, polyoxethylene glycols, and polytetrafluoroethylene, and inorganic materials such as talc and dicalcium phosphate, and sodium starch glycolate.

20 19. The composition according to any one of claims 9 to 18, wherein the composition is an intradermal composition.

20. The composition according to claim 19, wherein the intradermal composition comprises an aqueous medium.

25

21. The composition according to claim 20, wherein the aqueous medium is selected from 0.9% NaCl saline solution 0.9% KCl saline solution, Ringer's lactate solution, Acetated Ringer's solution, Intravenous sugar solutions, 5% dextrose in normal saline (D5NS), 10% dextrose in normal saline (D10NS), 5%  
30 dextrose in half-normal saline (D5HNS), 10% dextrose in half-normal saline (D10HNS), Phosphate buffered saline (PBS), TRIS-buffered saline (TBS), Hank's balanced salt solution (HBSS), Earle's balanced salt solution (EBSS), Standard

- 37 -

saline citrate (SSC), HEPES-buffered saline (HBS), and Gey's balanced salt solution (GBSS).

22. The composition according to claim 20 or 21, wherein the weight ratio of  
5 the aqueous medium to the composition is about 0.1 %w/w to about 50 %w/w.

23. The composition according to any one of claim 19 to 22, wherein the  
intradermal composition comprises an excipient selected from  
carboxymethylcellulose sodium, microcrystalline cellulose, cresol,  
10 methylparaben, and propylparaben.

24. The composition according to claim 23, wherein the weight ratio of  
excipients to intradermal composition is about 0.1 %w/w to about 50 %w/w.

15 25. The composition according to any one of claims 9 to 18, wherein the  
composition is a topical composition selected from a topical cream or topical gel.

26. The composition according to claim 25, wherein the topical composition  
further comprises an excipient selected from a carrier, a emulsifier and/or a  
20 thickening agent.

27. The composition according to claim 25 or 26, wherein the topical  
composition further comprises an excipient selected from Arabic gum, acetic  
acid, acetone, acetyltributyl citrate, agar, ethanol, alginic acid, almond oil, alpha  
25 tocopherol, aluminium monostearate, aluminium stearate, aluminium oxide,  
ascorbic acid, ascorbyl palmitate, bentonite, benzalkonium chloride,  
benzethonium chloride, benzoic acid, benzyl alcohol, benzyl benzoate, boric  
acid, bronopol, butylated hydroxyanisole, butylated hydroxytoluene, butylene  
glycol, butylparaben, calcium acetate, calcium alginate, calcium chloride,  
30 calcium hydroxide, calcium lactate, carbomer, carboxymethylcellulose sodium,  
carrageenan, castor oil, microcrystalline cellulose, ceresin, cetostearyl alcohol,  
cetrimide, cetyl alcohol, chlorocresol, chloroxylenol, chlorosterol, citric acid,

- 38 -

colloidal silicon dioxide, cresol, crospovidone, cyclomethicone, denatonium benzoate, dibutyl phthalate, diethanolamine, dimethicone, dimethyl phthalate, dimethylacetamide, disodium edetate, docusate sodium, ethyl acetate, ethyl lactate, ethyl oleate, ethylene vinyl acetate, ethylparaben, gelatin, glycerine, 5 glyceryl monooleate, glyceryl monostearate, glycofufurol, hydroxyethyl cellulose, hydroxypropyl cellulose, hypromellose, imidurea, isopropyl alcohol, isopropyl myristate, isopropyl palmitate, kaolin, lactic acid, lanolin, lecithin, linoleic acid, silicate, malic acid, mannitol, methylcellulose, methylparaben, monothioglycerol, myristic acid, myristyl alcohol, oleic acid, oleyl alcohol, 10 palmitic acid, paraffin, petrolatum, phenoxyethanol, poloxamer, polycarbophil, polyethylene glycol, polymethylacrylate, polyoxyglyceride, polyvinyl alcohol, povidone, propylene glycol, propylparaben, pyrrolidone, sodium hydroluronate, sodium lactate, sodium lauryl sulfate, sorbitan ester, sorbitol, starch, tricaprylin, triethylanolamine, xanthan gum, or xylitol.

15

28. The composition according to claim 26 or 27, wherein the weight ratio of excipients to topical composition is about 0.1 %w/w to about 50 %w/w.

29. The composition according to any one of claims 9 to 18, wherein the 20 composition is applied to a transdermal patch.

30. The composition according to claim 29, wherein the composition is applied as a layer within the transdermal patch or applied on a surface of the transdermal patch.

25